OpenAI Enters Drug Discovery with GPT Rosalind. On April sixteenth, OpenAI launched a new model purpose built for biochemistry and genomics, squaring off against Google’s Isomorphic Labs. Combined with Anthropic’s four hundred million dollar acquisition of Coefficient Bio, frontier AI labs are now placing direct bets on the life sciences stack.
Eli Lilly’s LillyPod and the Compute Arms Race. Lilly inaugurated the world’s first NVIDIA DGX SuperPOD with DGX B three hundred systems, delivering over nine thousand petaflops of AI performance. We explore why industry leaders are building AI native operating models now and letting regulation catch up.
FDA and EMA Align on AI Principles. With regulators now demanding transparency, lifecycle controls, and explainable logic, we discuss what a mature AI governance framework looks like and why boards need to own this topic directly.
From Models to Molecules. The industry language has shifted. The first AI designed drug candidates are approaching phase three milestones, and platformization plus AI fluency are redrawing the clinical trial value chain. We also cover biosecurity concerns, AWS Amazon Bio Discovery, and why only twenty percent of biopharma companies are considered digitally maturing.